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A compelling body of evidence indicates that 
endothelial progenitor cells (EPCs) of BM ori-
gin play a critical role in postnatal physiological 
and pathophysiological vasculogenesis (1, 2) 
and hold great potential to modulate the course 
of ischemic disease (3, 4) and tumor biology 
(5). In the BM, the adhesion interaction be-
tween stem/progenitor cells and the stromal 
microenvironment is essential in the homing, 
retention, and migration of hematopoietic stem 
cells and in hematopoiesis (6–10). Both α4 in-
tegrins, α4β1 and α4β7, have been shown to 
play key roles in these processes via interactions 
with ligands expressed on the surface of endo-
thelial and stromal cells or in the extracellular 
matrix (6, 11–15).
During mobilization of hematopoietic pro-
genitor cells (HPCs), expression of α4 integrin 
is substantially down-regulated (16, 17). Early 
hematopoietic cytokines that induce the transi-
tion of quiescent primitive HPCs into the syn-
thetic, or S phase, of the cell cycle have also 
been shown to markedly reduce α4 integrin 
expression and the binding of HPCs to the ex-
tracellular matrix (16, 18). The formation of 
a highly proteolytic microenvironment in the 
BM and the subsequent proteolytic cleavage 
of vascular cell adhesion molecule (VCAM)-1, 
a major ligand of α4 integrins, have been found 
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The cell surface receptor 𝗂4 integrin plays a critical role in the homing, engraftment, 
and maintenance of hematopoietic progenitor cells (HPCs) in the bone marrow (BM). 
Down-regulation or functional blockade of 𝗂4 integrin or its ligand vascular cell adhesion 
molecule-1 mobilizes long-term HPCs. We investigated the role of 𝗂4 integrin in the 
mobilization and homing of BM endothelial progenitor cells (EPCs). EPCs with endothelial 
colony-forming activity in the BM are exclusively 𝗂4 integrin–expressing cells. In vivo, a 
single dose of anti–𝗂4 integrin antibody resulted in increased circulating EPC counts for 
3 d. In hindlimb ischemia and myocardial infarction, systemically administered anti–𝗂4 
integrin antibody increased recruitment and incorporation of BM EPCs in newly formed 
vasculature and improved functional blood fl  ow recovery and tissue preservation. Interest-
ingly, BM EPCs that had been preblocked with anti–𝗂4 integrin ex vivo or collected from 
𝗂4 integrin–defi  cient mice incorporated as well as control cells into the neovasculature in 
ischemic sites, suggesting that 𝗂4 integrin may be dispensable or play a redundant role in 
EPC homing to ischemic tissue. These data indicate that functional disruption of 𝗂4 
  integrin may represent a potential angiogenic therapy for ischemic disease by increasing 
the available circulating supply of EPCs.
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to be critical steps in growth factor– or   chemokine-induced 
mobilization of BM stem cells (19). In addition, direct anti-
body blockade of either VCAM-1 or α4 integrin mobilizes 
long-term repopulating HPCs in rodents and primates (7, 20, 
21). Moreover, conditional knockout of α4 integrin in mice 
leads to a redistribution of the hematopoietic stem cell pool 
between the BM and the peripheral blood, favoring move-
ment to the peripheral blood (22, 23).
Although the role of α4 integrin in HPC homeostasis has 
been established, its role in the mobilization, tissue homing, 
and function of BM EPCs has not yet been defi  ned. In the 
current study, we present evidence that functional blockade of 
α4 integrin signifi  cantly mobilizes EPCs from the BM into the 
peripheral circulation, augments functional neovascularization, 
and enhances tissue preservation after ischemic injury.
RESULTS
BM colony-forming EPCs express 𝗂4 integrin
We fi  rst performed fl  ow cytometry analysis and found that 
the majority of isolated bone marrow mononuclear cells 
(BMMNCs) expressed α4 integrin (Fig. 1 A). To investigate 
whether BM α4 integrin–positive populations contain pri-
mitive EPCs in the steady-state, we used FACS to obtain 
equal numbers of CD45+α4+ and CD45+α4− cells from 
the BMMNCs, then conducted a two-step EPC colony cul-
ture assay. The EPC colonies were identifi  ed by double stain-
ing for DiI-acLDL uptake and isolectin B4-FITC binding 
(Fig. 1 B, left). Primitive EPCs with colony-forming poten-
tial were exclusively α4 integrin–positive (Fig. 1 B, right). More-
over, fl  ow cytometric analysis of BMMNCs using triple 
staining for α4 (or CD45) with two surrogate EPC markers, 
Sca-1 and Flk-1, demonstrated that only α4+ or CD45+ pop-
ulations, not α4− or CD45− cells, contain Sca-1 and Flk-1 
double-positive cells (Fig. 1, C and 1D). These results are in 
agreement with the EPC colony assay (Fig. 1 B) and further 
suggest a possible role of α4 integrin in EPC homeostasis in 
the BM.
Functional blockade of 𝗂4 integrin increases 
circulating EPCs
To investigate whether blockade of α4 integrin mobilizes 
BM EPCs to the peripheral blood (PB), we injected PS/2, a 
monoclonal  α4 integrin–blocking antibody (Ab) i.v. into 
wild-type mice. After 24 h, peripheral blood mononuclear 
cells (PBMNCs) were isolated, and fl  ow cytometry analysis 
was performed using the EPC markers Sca-1 and Flk-1. We 
found a substantial increase in circulating Sca-1+Flk-1+ dou-
ble-positive cells in the Ab-treated mice compared with con-
trol IgG-treated mice (Fig. 2 A). The circulating EPCs 
(circEPCs) were also evaluated by EPC culture assay using 
isolated PBMNCs. The Ab treatment signifi  cantly increased 
the number of circEPCs, indicated by the increase in adher-
ent cells double positive for DiI-acLDL uptake and isolectin 
B4 binding after culture (Fig. 2 B). In fact, we detected a 
higher level of circEPCs for up to 3 d after a single injection 
of the anti–α4 Ab in the time course study (Fig. 2 C). 
Figure 1.  Colony-forming EPCs express 𝗂4 integrin in the BM. 
(A) Flow cytometric analysis of α4 integrin expression in mouse BMMNCs. 
(B) Colony-forming EPCs were evaluated with a two-step endothelial cell 
differentiation culture starting with 5 × 106 CD45+α4+ or CD45+α4− 
FACS-sorted BMMNCs (A, red and blue frame, respectively). The left panel 
shows a typical colony of EPCs double positive for DiI-acLDL uptake (red) 
and isolectin B4–FITC binding (green), appearing yellow on merged im-
ages. The right panel shows the counts of double-positive colonies grown 
from CD45+α4+ and CD45+α4− BMMNCs, respectively (n = 3 per group; 
***, P < 0.001). (C and D) Flow cytometric analysis of stem cell antigen-1 
(Sca-1) and FMS-like kinase (Flk-1) expression in α4+ vs. α4-BMMNC or 
in CD45+ vs. CD45− BMMNC, respectively.JEM VOL. 203, January 23, 2006  155
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We also performed the EPC culture assay using PBMNCs 
from conditional α4 integrin knockout mice, those in which 
 97% of the BMMNCs had lost α4 integrin expression after 
induction of cre expression (22). The knockout mice dem-
onstrated a signifi  cantly greater number of circEPCs com-
pared with their WT littermates (Fig. 2 D). These data 
indicate that specifi  c disruption of the α4 integrin molecule 
increases the number of circEPCs.
Blockade of 𝗂4 integrin dissociates adherent BM EPC 
from VCAM-1 or BM stroma ex vivo
Because VCAM-1 has been shown to be a major ligand of 
stem cell α4 integrin in the BM, we investigated whether α4 
integrin–blocking Ab interferes with the adhesion interaction 
between α4 integrin and VCAM-1, postulating that such in-
terference could contribute to anti–α4 integrin Ab–induced 
EPC mobilization. We applied freshly isolated BMMNCs to 
immobilized recombinant VCAM-1 in cell culture plates. 
The anti-α4 integrin Ab not only blocked BMMNC adhe-
sion to VCAM-1 when added before the cells, but also com-
peted with this adhesion in a dose-dependent manner when 
added after the cells (Fig. 3 A, top). Cells suspended after the 
addition of Ab were harvested and seeded for an EPC col-
ony–forming assay. The number of EPC colonies grown from 
the suspended cells was proportionate to the total number of 
suspended cells (Fig. 3 A, bottom), suggesting that VCAM-1 
supports α4 integrin–mediated EPC attachment and that α4 
integrin–blocking Ab fosters EPC release. We also performed 
adhesion assays using another α4 integrin ligand, fi  bronectin 
(FN), and another extracellular matrix molecule, intercellular 
cell adhesion molecule (ICAM)-1, in parallel with VCAM-1. 
FN and ICAM-1 conferred lower levels of BMMNC ad-
hesion compared with VCAM-1 (Fig. 3 B). The anti–α4 Ab, 
however, did not signifi  cantly compete or block adhesion of 
BMMNCs to FN or ICAM-1 (Fig. 3 B).
Because other α4 integrin ligands in the BM in addition 
to VCAM-1 and fi  bronectin may be involved in α4   integrin–
dependent adhesion between EPCs and the stroma, we per-
formed an additional adhesion assay using single-layer stromal 
cells grown from total mouse BM. Again, anti–α4 in  tegrin 
Ab signifi  cantly blocked and competed the adhesion of EPCs 
to the BM stroma in a dose-dependent manner (Fig. 3 C), 
suggesting that the Ab may release BM EPCs from α4 integ-
rin–mediated attachment in the BM.
In vivo blockade of 𝗂4 integrin increases level of circEPCs 
in the setting of ischemia
Because tissue ischemia has been shown to induce EPC mo-
bilization (24), we examined the eff  ect of α4 integrin block-
ade on the level of circEPCs after ischemia. We surgically 
induced hind limb ischemia (HLI) by excision of the left 
femoral artery in mice and randomized them to receive im-
mediate anti–α4 integrin Ab or control IgG twice per week 
for 3 wk. As shown in Fig. 4, anti–α4 integrin Ab signifi  cantly 
increased the degree and the duration of HLI-induced EPC 
elevation in the peripheral circulation.
In vivo blockade of 𝗂4 integrin augments BM EPC-mediated 
neovascularization after ischemia and improves recovery of 
functional blood fl  ow
We used two mouse ischemia models, Tie2/LacZ BM trans-
plantation plus hindlimb ischemia (Tie2/LacZ-BMT+HLI) 
and Tie2/GFP BM transplantation plus myocardial infarction 
(MI) (Tie2/GFP-BMT+MI), to investigate whether BM 
EPC mobilization induced by α4 integrin blockade aff  ects 
angiogenesis. In the Tie2/LacZ-BMT+HLI model, we re-
constituted the BM of WT mice with BMMNCs genetically 
marked with Tie2/LacZ, which allows for easy detection of 
BM-derived cells with immunofl   uorescent staining for 
β-galactosidase (β-gal). After surgical induction of HLI, the 
mice received periodic injections with either anti–α4 integ-
rin Ab or control IgG. As shown in Fig. 5 A, the Ab-treated 
mice exhibited accelerated blood fl   ow recovery compared 
Figure 2.  Single dose of anti–𝗂4 integrin Ab signifi  cantly in-
creases circEPCs. (A) Flow cytometric analysis for the Sca-1+Flk-1+ cells 
in PBMNCs isolated at 24 h after i.v. injection of 200 µg anti–α4 integrin 
Ab (n = 7 per group; **, P < 0.01). (B) EPC culture assay using PBMNCs 
isolated at 24 h after i.v. injection of 200 µg anti–α4 integrin Ab. EPCs 
were cultured for 4 d then identifi  ed as adherent cells double positive for 
DiI-acLDL uptake (red) and isolectin B4–FITC binding (green) (left, original 
magnifi  cation, 200×) (right, ***, P < 0.001). (C) EPC culture assay using 
PBMNCs isolated at various time points after a single i.v. injection of 
200 µg anti–α4 integrin Ab (○, control IgG; ▲, anti–α4 integrin Ab; 
n = 4 per group at each time point; **, P < 0.01; *, P < 0.05). (D) EPC 
culture assay using PBMNCs from α4 integrin conditional knockout mice 
or WT controls (n = 4; ***, P < 0.001).156  BLOCKADE OF α4 INTEGRIN MOBILIZES EPCS | Qin et al.
with the IgG-treated animals, when assessed on days 7, 11, and 
14. In addition, there was a signifi  cantly greater number of 
endothelial cells (ECs) of BM origin in the ischemic limb in 
the Ab-treated mice compared with the IgG-treated mice, 
when examined 14 d after induction of HLI (Fig. 5, B and C). 
The overall capillary density was also signifi  cantly higher in the 
Ab-treated mice (Fig. 5 C). Ab treatment conferred better 
long-term preservation of muscle tissue, as assessed by the ratio 
of muscle weight in ischemic limbs to normal limbs at 60 d after 
induction of HLI (Fig. 5 D). The endothelial identity of BM-
derived cells incorporated in the neovasculature of the isch-
emic tissues was further confi  rmed by immunofl  uorescent 
staining for another independent endothelial marker, CD31, 
along with β-gal (Fig. 5 E).
We further evaluated the EPC-mediated proangiogenic 
eff  ect of α4 integrin blockade in the Tie2/GFP-BMT+MI 
model. MI was induced by permanent ligation at the mid-
dle of the left anterior descending (LAD) coronary artery. 
Again, Ab-treated mice exhibited a signifi  cantly greater 
number of BM-derived ECs in the infarcted heart, indi-
cated by a greater number of cells staining positive for both 
Tie2-driven GFP  and  Bandeiraea simplicifolia (BS) lectin 
I–Rhodamine (Fig. 6, A and B). Interestingly, we also de-
tected signifi  cantly more preexisting capillaries that survived 
Figure 3.  Anti–𝗂4 integrin Ab blocks and competes for BM EPC 
adhesion to VCAM-1 and BM stroma. (A, top) Adhesion of freshly 
isolated mouse BMMNCs to the immobilized VCAM-1 was quantifi  ed with 
crystal violet microtiter plate. The Ab was added either before (Ab block) 
or 15 min after (Ab compete) the application of cells. The total incubation 
time of the Ab with cells was 30 min. (A, bottom) EPC colony assay using 
Figure 4.  Anti–𝗂4 integrin Ab augments EPC mobilization after 
ischemic injury. FVB/NJ mice received surgically induced left HLI and 
were immediately randomized to receive injections of α4 integrin–
  blocking Ab or control IgG twice per week. Five mice in each group were 
killed at each data point (presurgery, 1, 2, or 3 wk post-HLI surgery), and 
PBMNC EPC culture assays were performed. (○, control IgG; ▲, anti–α4 
integrin Ab; **, P < 0.01; ***, P < 0.001).
the suspension cells that resulted from each treatment in the top 
(***, P < 0.001 compared with blank control or isotype control; n = 3 per 
treatment). (B) Similar adhesion assay using different extracellular matrix 
or antibodies (V, VCAM-1; I, ICAM-1; FN, fi  bronectin; B/20 or B/200, 
block with 20 or 200 µg/ml Ab, respectively; C/2, C/20, or C/200 compete 
with 2, 20, or 200 µg/ml, respectively; n = 3 per treatment; **, P < 0.01; 
***, P < 0.001 compared with VCAM-1 coating without Ab group; 
‡, P < 0.01 compared with ICAM-1 coating without Ab group. (C) Adhe-
sion of isolated BMMNCs on ex vivo cultured monolayer BM stroma. 
Quantifi  cation was performed by counting the number of adherent cells 
per square unit and expressed as a percentage (***, P < 0.001 compared 
with isotype control).JEM VOL. 203, January 23, 2006  157
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(BS lectin I–Rhodamine+GFP−) in the infarcted area (Fig. 
6, A and C) and a signifi  cantly higher capillary density in 
the periinfarct area in the Ab-treated mice compared to 
controls (Fig. 6 D). α4 integrin blockade signifi  cantly re-
duced both the left ventricular fi  brosis area (Fig. 6, E and F) 
and left ventricular dilation (Fig. 6, E and G) when exam-
ined 2 wk after infarction, suggesting a favorable eff  ect of 
α4 integrin blockade on the remodeling of the infarcted 
murine heart.
Functional disruption of 𝗂4 integrin does not impair BM 
EPC homing or incorporation into neovasculature
α4 integrin may play an important role in leukocyte recruit-
ment during tissue infl  ammation (25). The recruitment of 
EPCs to ischemic tissue is a key feature in EPC-mediated vas-
culogenesis, but the role of α4 integrin has not been clear. 
Therefore, the increased number of BM EPCs in the ischemic 
neovasculature after systemic blockade of α4 integrin was in-
triguing. To investigate whether α4 integrin plays a role spe-
cifi  cally in EPC recruitment to ischemic tissue, we designed 
an in vivo EPC tissue homing assay. Isolated BMMNCs were 
pretreated ex vivo with either α4 integrin–blocking Ab or 
control IgG, labeled with DiI, and directly injected into the 
peripheral circulation of mice that had undergone surgical 
HLI and splenectomy without irradiation. This experimental 
design was used to minimize sequestering of EPCs (in the 
spleen) thereby providing the best opportunity to examine the 
impact of α4 blockade on tissue homing. Interestingly, 
BMMNCs pretreated with α4 integrin–blocking Ab were as 
well represented as BMMNCs pretreated with control IgG 
in the neocapillaries formed in the ischemic limb. We found 
Figure 5.  Tie2/LacZ-BMT+HLI mouse model. Tie2/LacZ BM-trans-
planted recipient FVB/NJ mice received surgically induced left HLI and 
were randomized to receive injections of α4 integrin–blocking Ab or con-
trol IgG twice per week. On day 14, 10 mice from each group received i.v. 
injections of BS lectin I–FITC, which identifi  es vasculature, and were killed. 
(A) Laser Doppler Perfusion Image showing recovery of blood fl  ow after 
surgery, expressed as the ratio of perfusion in ischemic limbs to normal 
limbs (left panel □ control IgG; ■ anti–α4 integrin Ab. **, P < 0.01; 
*, P < 0.05). On the right are representative Laser Doppler Perfusion Im-
ages at various time points. (B) Representative fl  uorescent microscope 
fi  elds of capillaries (BS lectin I–FITC+, green) and BM-derived EPCs (anti–
β-gal–Rhodamine staining+, red) at ischemic area (original magnifi  cation, 
400×). Arrows indicate BS lectin 1 and β-gal double positive cappillaries. 
(C) Overall capillary density (BS lectin I–FITC-positive only) (left, n = 6 
limbs per group; **, P < 0.01) and BM EPC–derived capillary density (BS 
lectin I–FITC and β-gal–Rhodamine double positive) (right, n = 6 limbs 
per group; ***, P < 0.001) in the ischemic area. (D) The rest of the 10 mice 
in each group were killed on day 60. The wet muscular tissue of the lower 
limbs was isolated and weighed. Tissue preservation was expressed as the 
ratio of muscle weight in ischemic limbs to normal limbs (**, P < 0.01). 
(E) Immunofl  uorescent double staining for another endothelial marker, 
CD31 (red) and β-gal (blue) was performed on ischemic limbs at day 14 
post-HLI (top) (original magnifi  cation, 200×). Arrows indicate CD31 and 
β-gal double positive capillaries. Quantifi  cation of CD31+ capillary density 
(bottom left, n = 6 limbs per group; **, P < 0.01) and CD31 + β-gal + 
double-positive BM EPC-derived capillary density (pink) (bottom, n = 6 
limbs per group; ***, P < 0.001).158  BLOCKADE OF α4 INTEGRIN MOBILIZES EPCS | Qin et al.
Figure 6.  Tie2/GFP−BMT+MI mouse model. Myocardial infarction 
was induced by ligation of the LAD in Tie2/GFP BM-transplanted mice. 
Mice were then randomized to receive i.v. injections of anti–α4 integrin Ab 
or control IgG twice weekly (n = 10 per group). On day 14, the mice re-
ceived i.v. injections of BS lectin I–Rhodamine and were killed. The in-
farcted hearts were sectioned in a bread loaf fashion and pathohistological 
analysis was performed. Shown here are sections obtained at the level of 
2 mm below the LAD ligation suture from each animal. (A) Representative JEM VOL. 203, January 23, 2006  159
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similar numbers of DiI-labeled and control EPCs incorporated 
in the neocapillaries (Fig. 7 A) and equal numbers of labeled 
cells from the two groups circulating in the PB. Because an 
equal number of BMMNCs were injected into the two groups 
of mice, these data indicate that the ex vivo α4 integrin block-
ade did not aff  ect EPCs homing or incorporation into neocap-
illaries, and further support the importance of the mobilization 
eff  ect  of  α4 integrin blockade on changes in ischemic 
tissue repair. Similar results were also obtained in mice 
without splenectomy.
To further confi  rm this observation and to overcome cer-
tain limitations of Ab blockade, such as unanticipated eff  ects 
in nontarget tissues, BMMNCs were isolated from α4 integrin 
conditional knockout mice. WT litter mates served as con-
trols. We injected these BMMNCs into background-matched 
WT mice that had undergone surgical MI and splenectomy. 
Again, loss of α4 integrin did not impair incorporation of the 
injected BM EPCs into the neovasculature of infarcted cardiac 
tissue (Fig. 7 B), consistent with the results obtained from the 
in vivo homing assay using α4 integrin–blocking Ab. These 
results confi  rm that loss of α4 integrin does not impair EPC 
homing to ischemic tissue.
DISCUSSION
In this study, we demonstrated that blockade of α4 integrin 
promotes mobilization of BM EPCs to the peripheral circu-
lation and promotes functional neovascularization after ische-
mia. Several lines of evidence support this conclusion. First, 
primitive, colony-forming EPCs in isolated BMMNCs are 
Figure 7.  Functional disruption of 𝗂4 integrin does not alter EPC 
tissue homing properties. (A) Equal numbers (15 × 106) of BMMNCs 
were pretreated with either anti–α4 integrin Ab or control IgG, labeled 
with DiI, and injected into the peripheral circulation of mice with surgi-
cally induced HLI and splenectomy. On day 7, the mice were injected 
with BS lectin I–FITC and killed. Pathological analysis was conducted on 
the ischemic limb tissues. Capillaries in which ECs derived from injected 
BM EPCs were incorporated are BS lectin I–FITC and DiI double positive 
(top, the representative fl  uorescent microscopy; original magnifi  cation, 
200×) (bottom, quantifi  cation of the densities of   double-positive capil-
laries; n = 6 per group). (B) Background-matched, splenectomized WT 
recipient mice that had MI induced by LAD ligation received i.v. injec-
tions of 106 BMMNCs from either α4 integrin conditional knockout mice 
or WT littermates. On day 7, the recipients were injected with BS lectin 
I–FITC and killed. The ischemic cardiac tissues were sectioned. Neovas-
cular tissue containing ECs derived from the injected BM EPCs appear 
BS lectin I–FITC and DiI double positive (top, representative fl  uorescent 
microscopy; original magnifi  cation 400×) (bottom, quantifi  cation of 
the densities of double-positive capillaries; n = 6 per group). Arrows 
indicate double positive capillaries in both panels.
fl  uorescent microscopy of the infarct areas (original magnifi  cation, 200×; 
BM-derived ECs, double positive for GFP [green] and BS lectin I–Rhoda-
mine [red; appear yellow in the merged pictures and are indicated with 
arrows]). (B) Density of the capillaries with incorporated  BM-derived ECs 
in the ischemic areas (n = 6 per group; ***, P < 0.001).  (C) Preexisting 
survival capillary density in the infarct areas (BS lectin  I–Rhodamine+ 
only) (n = 6 per group; ***, P < 0.001). (D) Capillary   density in the periin-
farct area (n = 6 per group; ***, P < 0.001). (E) Representative Masson’s 
Trichrome staining of hearts after MI. The blue color represents fi  brosis or 
scar which appears reduced in the hearts from anti–α4 Ab treatment 
group. Bar, 1 mm. (F) Quantifi  cation of area of fi  brosis (d/c × 100%) con-
fi  rms a reduction in LV fi  brosis after MI in anti-α4 Ab–treated animals 
(n = 12 per group; **, P < 0.01). (G) Histological dimensions ((a+b)/2) 
(n = 12 per group; **, P < 0.01).160  BLOCKADE OF α4 INTEGRIN MOBILIZES EPCS | Qin et al.
exclusively α4 integrin–expressing cells. Second, anti–α4 
  integrin Ab blocks and competes with the adhesive interac-
tion between BM EPCs and immobilized VCAM-1 or BM 
stroma ex vivo. Third, systemic administration of anti–α4 
integrin Ab or conditional knockout of α4 integrin in the 
BM   signifi  cantly increases circEPCs. Fourth, after ischemic 
injury, anti–α4 integrin Ab fosters homing of BM-derived 
EPCs to the neovasculature at ischemic tissue and aug-
ments recovery of blood fl  ow and tissue preservation. Our 
study establishes for the fi  rst time that α4 integrin plays an 
important role in EPC mobilization and that functional 
disruption of α4 integrin–mediated EPC lodgment in the 
BM causes a shift toward a distribution of EPCs that is more 
favorable for neovascularization.
Anti–α4 integrin blocking Ab has previously been shown 
to mobilize BM HPCs (26). These cells, in turn, have been 
shown to contribute to neovascularization at ischemic sites 
by secreting a spectrum of growth factors and supporting the 
establishment of EPCs (2, 27). Because Tie2 expression has 
also been found in a subset of HPCs (28, 29), it is possible 
that the potent proangiogenic eff  ect of anti–α4 integrin Ab 
treatment observed in our study may have resulted from the 
combined mobilization of circEPCs and HPCs.
Granulocytes, macrophages, and lymphocytes have been 
shown to secrete various pro- and antiangiogenic factors in 
ischemic tissue and play complex roles in recovery after 
ischemia (30, 31). It has also been shown that α4 integrin 
plays a role in cytokine-induced leukocyte–endothelium 
interactions (32–34) and that blockade of α4 integrin in-
hibits infl  ammatory cell recruitment (25, 35–37). Consis-
tent with these prior observations, we noted a decrease in 
F4/80-  positive cells in the ischemic limbs of the Ab-treated 
mice (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20050459/DC1).  Although the mechanism of 
EPC migration to ischemic tissue has been under intensive 
investigation, the role α4 integrin plays in this process is 
not yet elucidated. Some evidence suggests that α4 in  tegrin 
may be unimportant for stem/progenitor cell tissue hom-
ing and migration, because α4 integrin levels are substan-
tially down-regulated on mobilized stem cells in PB (16, 
17, 38), whereas activated, migrating infl  ammatory cells 
express abundant α4 integrin (39). It has recently been 
shown that circEPCs isolated from human PB express low 
levels of α4 integrin (40) and that neutralizing Ab to VLA-4 
signifi   cantly inhibits adherence of BM CD34+, but not 
mobilized PB CD34+ stem cells, to stromal cells, suggest-
ing the existence of alternative cell adhesion molecules that 
mediate circulating stem cell binding (41). In addition, it 
has been reported that α4 integrin is necessary for the 
homing and lodgment of stem/progenitor cells to BM, but 
not to spleen (7, 22, 42). However, α4 integrin may play a 
role in soluble VCAM1-induced migration and angiogen-
esis in HUVECs (43), as recently reported.
In the current study, we found that neither ex vivo block-
ade nor genetic knockout of α4 integrin prevents EPC hom-
ing to ischemic tissue, suggesting that adhesion activity of 
α4 integrin is not essential for homing of circEPCs to isch-
emic tissue in the setting of acute ischemia. Coincidently, 
it has recently been shown that β2 integrin may play a more 
prominent role in the homing of EPCs to ischemic skeletal 
muscle (44).
Despite the fact that several other β1 integrins are 
known to be essential to various angiogenesis processes, 
the direct role of α4β1 integrin in angiogenesis and vas-
culogenesis   remains largely obscure (45–47). Limited stud-
ies in experimental models suggest that α4 integrin may 
play a role in   angiogenesis induced by TNF-α and soluble 
VCAM-1 but not by basic fi  broblast growth factor (43, 
48). Studies currently underway in our lab suggest that 
TNF-α signaling is indeed required for ischemic angio-
genesis (49). Unfortunately, with the exception of TNF-α, 
the stimuli for angiogenesis during tissue ischemia are not 
well understood at this time. Nevertheless, the eff  ect of 
anti–α4 integrin treatment on local angiogenesis warrants 
further investigation.
A VLA-4–dependent mechanism has previously been 
shown to play an important role in mononuclear leukocyte 
emigration during early atherosclerosis (50), neointimal for-
mation after vessel injury (51), and neutrophil-mediated car-
diac myocyte dysfunction (52). Blockade of α4 integrin has 
been shown to attenuate atherosclerosis (53) and reduce 
postinjury intimal hyperplasia (54, 55) and neoadventitial for-
mation (56) in animals. Our study indicates that α4 integrin 
blockade enhances the mobilization of EPCs and EPC-medi-
ated neovascularization. These data suggest a novel therapeu-
tic strategy for stimulating therapeutic neovascularization in 
acute and chronic ischemia. Moreover, the rapidity and du-
rability of EPC mobilization induced by a single dose of anti–α4 
Ab compare favorably with currently available agents such as 
G-CSF (57) and may make this approach a practical addition 
to the therapeutic armamentarium.
MATERIALS AND METHODS
Antibodies. The antimurine α4 integrin mAb PS/2 was purifi  ed from 
cultured hybridoma cells (American Type Culture Collection) using 
Montage Antibody Purifi  cation kits. The antimurine ICAM-1 blocking 
Ab was purchased from R & D Systems. All other Abs and isotype con-
trols were purchased from BD Biosciences. A second mAb against a dif-
ferent recognition site of α4 integrin was used to confi  rm the specifi  city 
of the purifi  ed PS/2 Ab with fl  ow cytometry analysis. The isotype control 
IgG of PS/2, rat IgG2b, was dialyzed to remove sodium azide when used 
in vivo.
Animals. Male FVB/NJ and background-matched Tie2/LacZ or Tie2/
GFP transgenic mice were purchased from the Jackson Laboratories. The 
conditional α4 integrin knockout mice (Mx.cre+α4fl  ox/fl  ox) and control litter-
mates (α4fl  ox/fl  ox) were generated as described previously (22). The mice 
were maintained and operated following protocols proved by the Caritas 
St. Elizabeth’s Institutional Animal Care and Use Committee.
Flow cytometry analysis and FACS sorting. Mouse BMMNCs or 
PBMNCs were isolated with density-gradient centrifugation (58). Flow cy-
tometry analysis and FACS sorting of the isolated BMMNCs or PBMNCs 
were performed as previously described (58).JEM VOL. 203, January 23, 2006  161
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BMMNC EPC colony assay and PB circEPC culture assay. Taking 
advantage of the late growth and high proliferative properties of primitive 
EPCs, we developed a two-step EPC colony assay. The isolated mouse 
BMMNCs were cultured in 0.1% vitronectin/gelatin-coated plates in EBM-2 
complete medium (EBM-2 basal medium supplemented with the cytokine 
cocktail in endothelial growth medium-2–microvascular; SingleQuots, Clo-
netics, Inc.) (59). To evaluate BM colony–forming EPCs, 5 × 106 FACS-
sorted CD45+α4− or CD45+α4+ cells were cultured in a 6-well plate for 
4 d and then resplit into a 10-cm plate, cultured for another 7 d. DiI-acLDL 
(1:500) was added, and the cells were incubated for 4 h. The cells were then 
washed with PBS, fi  xed in 1% PFA, and stained with isolectin B4-FITC 
(1:200). Cell colonies double positive for DiI-acLDL uptake and isolectin 
B4-FITC binding were counted. The numbers of EPC colonies refl  ected 
the number of primitive EPCs in the initial sorted cell fractions.
To count circEPCs, an EPC culture assay was performed as previously 
described (59). In brief, the PBMNCs isolated from a 500-µl sample of PB 
were cultured in vitronectin-coated 4-well chamber slides in EBM-2 com-
plete media. On day 4 of the culture, DiI-labeled acLDL was added to the 
media. After incubating 4 h, the cells were fi  xed in 1% paraformaldehyde 
and counterstained with isolectin B4-FITC. Double-positive cells were 
counted as EPCs, the number of which refl  ected the number of initial cir-
cEPCs in the 500-µl sample.
Adhesion assay. 90 6-well tissue culture plates were coated with 10 μg/ml 
recombinant murine VCAM-1 or ICAM-1 (R & D Systems), or 50 μg/ml 
rat plasma fi  bronectin (Sigma-Aldrich). Freshly isolated BMMNCs (5 × 105) 
were added to each well. Antibodies were added either just before addition 
of the BMMNCs to block adhesion, or 15 min after the addition of cells to 
compete with adhesion. The cells and antibodies were coincubated in a 5% 
CO2 incubator at 37°C for 30 min. After incubation, nonadherent and 
loosely attached cells were removed by tapping each plate and gently wash-
ing the wells three times with Dulbecco’s phosphate-buff  ered saline. Cells in 
the group with 100% attachment were not washed. Attached cells were fi  xed 
in 5% glutaraldehyde, stained with 0.1% crystal violet, and solubilized in 10% 
acetic acid. A microplate reader was used to measure the absorbance at 564 
nm. The background crystal violet staining level was subtracted from read-
ings, and the values were expressed as the percentage of attachment. To ex-
amine the eff  ect of α4 integrin–blocking Ab on BMMNC adhesion to BM 
stromal cells, a single layer of BM stroma was prepared as previously de-
scribed (60). Adherent cells were counted during microscopic examination, 
and the result expressed as the ratio of the number of adherent cells in each 
experimental group to the number in the 100% attachment group.
Mouse Tie2/LacZ-BMT+HLI model. This procedure was preformed as 
previously described (61–63). See supplemental Materials and methods, avail-
able at http:// www. jem. org/cgi/content/full/jem.20050459/DC1, for details.
Mouse Tie2/GFP−BMT+MI model. BM transplantation and quantifi  ca-
tion of engraftment were performed (see supplemental Materials and meth-
ods) using Tie2/GFP mice as donors. Myocardial infarction was induced in 
recipient mice under artifi  cial ventilation by permanent ligation of the mid-
dle of the left anterior descending (LAD) coronary artery. Mice were ran-
domized to receive i.v. injection of either 200 µg of anti–α4 integrin Ab or 
control IgG, twice weekly starting on day 1. On day 14, the mice were in-
jected with 50 µl of BS lectin I–Rhodamine (Vector Laboratories) at the 
apex of the left ventricle (LV), and after 5 min the cardiac vasculature was 
perfused with 4% PFA through the right carotid artery with distal aortic arch 
clamped. Cardiac tissue was fi  xed for 1 h in 4% PFA, incubated in 30% su-
crose solution overnight, snap frozen in liquid nitrogen, and preserved at 
−80°C. Serial cryosectioning was performed starting at 1 mm below the su-
ture (used to ligate the LAD) moving toward the apex, with three consecu-
tive sections per 1 mm to allow for quantitative pathohistological analysis at 
each level (see next paragraph). Three sections per ischemic heart and 9 fi  elds 
per section (6 fi  elds in the infarct border zone, 3 fi  elds in the infarct area) 
were examined with BS lectin I–Rhodamine+ to quantify total capillary 
density or with Rhodamine+GFP+ to determine BM EPC-derived capillary 
density. Masson’s Trichrome staining was performed as previously described 
(64). The fi  brosis area was calculated as the ratio of the length of fi  brotic area 
to the length of LV inner circumference (Fig. 5 E, d/c), and the LV dimen-
sion was quantifi  ed histologically (Fig. 5 E, (a+b)/2). All surgical procedures 
and patho/histological analysis was performed by investigators blinded to 
treatment assignment.
In vivo BM EPC homing to ischemic tissue. BMMNCs were isolated 
from donor WT mice. Equal numbers of the cells were either blocked with 
anti–α4 integrin Ab or treated with control IgG. Cells were then labeled 
with DiI cell tracer and washed thoroughly. Recipient mice underwent ex-
cision of the left femoral artery to induce HLI and underwent splenectomy 
without irradiation. Mice were then randomized to immediately receive by 
tail vein injection either 15 × 106 BMMNCs that had been treated with 
anti–α4 integrin Ab or 15 × 106 cells that had been treated with control 
IgG. The circulating DiI-labeled cells in the PB were monitored on days 1, 
3, and 7 by fl  ow cytometry or fl  uorescent analysis of PBMNCs. No diff  er-
ence was found between the two groups of recipient mice (unpublished 
data). On day 7, the mice were injected with BS lectin I–FITC and killed. 
The capillaries derived from injected BMMNCs, which were double posi-
tive for BS lectin I–FITC and DiI, were examined microscopically and 
quantifi  ed. In another similar independent experiment, BMMNCs isolated 
from α4 integrin conditional knockout mice ( 97% of cells defi  cient for α4 
integrin) or control WT littermates were used. 10 × 106 cells were injected 
i.v. into background-matched recipient mice that had undergone surgical 
MI and splenectomy. On day 7, the mice were injected with BS lectin 
I–FITC and killed. The ischemic cardiac tissue was processed as described 
before, and the neocapillaries derived from the injected BM EPCs in the 
ischemic area were quantifi  ed.
Statistics. Data are presented as average ± SEM. Comparison between two 
means was performed with an unpaired Student’s t test. Comparisons of 
more than two means were performed using ANOVA with Fisher PLSD 
and Bonferroni Dunn Post Hoc analysis. Statistical signifi  cance was assigned 
if P < 0.05.
Online supplemental material. Supplemental materials and methods 
describe mouse Tie 2/LacZ-BMT and the hindlimb ischemia model. Fig. S1 
depicts hindlimb mouse tissue injected with control IgG and anti-α4 Ab. 
Online supplemental material is available at http://jem.org/cgi/content/
full/jem.20050459/DC1.
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